FDA Panel Not Persuaded By Effectiveness Of BioMarin Duchenne Muscular Dystrophy Drug

U.S. Food and Drug Administration advisers were not convinced of BioMarin Muscular Dystrophy drug's efficacy based on clinical trials. Drisapersen, fell short in proving its effectiveness in patients suffering from Duchenne muscular dystrophy.